Digital Repository

Unresolved issues in anthelmintic pharmacology for helminthiases of humans

Show simple item record Geary, T.G. en_US Woo, K. en_US McCarthy, J.S. en_US Mackenzie, C.D. en_US Horton, J. en_US Prichard, R.K. en_US de Silva, N.R. en_US Olliaro, P.L. en_US Lazdins-Helds, J.K. en_US Engels, D.A. en_US Bundy, D.A.P. en_US 2014-10-29T09:32:06Z 2014-10-29T09:32:06Z 2010 en_US
dc.identifier.citation International Journal of Parasitology. 2010; 40(1): pp.1-13 en_US
dc.identifier.issn 0020-7519 (Print) en_US
dc.identifier.issn 1879-0135 (Electronic) en_US
dc.description Indexed in MEDLINE
dc.description.abstract Helminth infections are an important constraint on the health and development of poor children and adults. Anthelmintic treatment programmes provide a safe and effective response, and increasing numbers of people are benefitting from these public health initiatives. Despite decades of clinical experience with anthelmintics for the treatment of human infections, relatively little is known about their clinical pharmacology. All of the drugs were developed initially in response to the considerable market for veterinary anthelmintics in high- and middle-income countries. In contrast, the greatest burden caused by these infections in humans is in resource-poor settings and as a result there has been insufficient commercial incentive to support studies on how these drugs work in humans, and how they should best be used in control programmes. The advent of mass drug administration programmes for the control of schistosomiasis, lymphatic filariasis, onchocerciasis and soil-transmitted helminthiases in humans increases the urgency to better understand and better monitor drug resistance, and to broaden the currently very narrow range of available anthelmintics. This provides fresh impetus for developing a comprehensive research platform designed to improve our understanding of these important drugs, in order to bring the scientific knowledge base supporting their use to a standard equivalent to that of drugs commonly used in developed countries. Furthermore, a better understanding of their clinical pharmacology will enable improved therapy and could contribute to the discovery of new products en_US
dc.publisher Elsevier en_US
dc.title Unresolved issues in anthelmintic pharmacology for helminthiases of humans en_US
dc.type Review Article en_US
dc.identifier.department Parasitology en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


My Account